LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall ST announces its post-earnings coverage on Nike, Inc. (NYSE: NKE). The company announced its Q4 FY16 financial results after the markets closed on Tuesday, June 29, 2016. The sportswear giant beat earnings expectations, but revenue and futures orders fell slightly short of estimates, renewing concerns that growth in the world’s largest sports brand will be stunted amid increased competition. Register with us now for your free membership and see our complete earnings coverage on this equity at:

http://www.activewallst.com/register/

Today, AWS is promoting its earnings coverage on NKE. Get all of our free coverage by signing up to http://www.activewallst.com/registration-3/?symbol=NKE.

Earnings Reviewed

For the quarter ended on May 31, 2016 the Beaverton, Oregon-based company posted diluted earnings of $0.49 per share on $8.24 billion in revenue. Earnings per share were flat from the year ago period, while revenue climbed 6% from$7.78 billion in Q4 FY15. Analysts expected Nike to report earnings of $0.48 per share on revenue of $8.28 billion.

Nike’s revenue of $3.74 billion from North America was flat from the year ago period. Revenue grew 19% and 18% on a y-o-y basis in Western Europe and Greater China, respectively. Japan’s revenue climbed 22% on y-o-y basis, while emerging markets sales declined 7%. Excess inventory issues in North America weighed on Nike’s Q4 FY16 gross margin, which dipped 30 basis points to 45.9%; this was also impacted by higher product costs and unfavourable exchange rates.

At the end of Q4 FY16, global futures orders for Nike products scheduled for delivery from June to November 2016 totalled $14.9 billion, an 8% increase on y-o-y basis and 11% higher on a currency neutral basis. This is a closely watched metric as it provides an indication of demand for Nike’s products in coming months. Orders in Japan are up 24% on y-o-y basis while it is up 18% in greater China. Meanwhile, orders from North America were up just 6% on y-o-y, the first time it has dipped into single digits since Q3 FY14 amid increased competition with sportswear titans such as Adidas and Under Armour Inc. (NYSE: UA).

Challenging Environment

After years of scorching growth, Nike is facing a number of challenges. Revenue in overseas market has been impacted by strong U.S. dollar, while competition in footwear market is heating up. Under Armour has been able to make progress in Nike’s long time stranglehold of the basketball shoes, while Adidas is increasing its market share in the sneaker segment. Nike basketball sales, other than Jordan Brand, declined 1% in Fiscal 2016 while Nike’s U.S. footwear overall rose just 2% in Q4 FY16, compared to a 16% rise in Q3 FY16. Nike has also been hampered by bankruptcy of Sports Authority and Eastern Mountain Sports stores in 2016 on which Nike relies heavily to sell its products.

Outlook

On the earnings conference call, Nike’s management said full-year expectations are “largely unchanged” from a growth and profitability perspective, in spite of the recent volatility spurred by the Brexit.

Share Buyback

During Q4 FY16, Nike repurchased a total of 9.0 million shares for approximately $540 million as part of its four-year, $12 billion program authorized by the board of directors in November, 2016.

Stock Market Performance

On Tuesday, June 28, 2016, Nike’s stock was up 2.31%, closing at $53.09 for the day. The stock recorded trading volume of 19.59 million, which was higher than its 3-month average volume of 9.92 million. Nike’s stock has declined 14.59% on YTD basis. In 2015, the company has topped gains in the Dow Jones Industrial Average with the stock advancing 30%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441787

LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Resorts & Casinos industry. Companies recently under review include Diamond Resorts Intl., Pinnacle Entertainment, Penn National Gaming, and Caesars Entertainment. See our complete report on Diamond Resorts Intl. at:

http://www.activewallst.com/registration-3/?symbol=DRII

Today, AWS is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

The Resorts and Casinos space encompasses a wide range of amenities and services, and competition in this industry is cutthroat. Additionally, in light of the current market volatility following the Brexit, let us see how these are affecting some of the big names in the industry. Register with us now for your free membership and more research reports at:

http://www.activewallst.com/register/

Active Wall St takes a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions.

Diamond Resorts International Inc. (NYSE: DRII)

On Tuesday, shares in Las Vegas, Nevada headquartered Diamond Resorts International Inc. recorded a trading volume of 938,980 shares. The stock ended the day at $24.07, gaining 2.78%. The Company’s shares have advanced 3.13% in the last one month and 2.56% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 7.60% and 2.41%, respectively. Furthermore, shares of Diamond Resorts International, which operates in the hospitality and vacation ownership industry in the continental U.S., Hawaii, Canada, Mexico, the Caribbean, Central America, South America, Europe, Asia, Australia, New Zealand, and Africa, have a Relative Strength Index (RSI) of 51.43.

Pinnacle Entertainment Inc. (NASDAQ: PNK)

Pinnacle Entertainment Inc’s stock finished yesterday’s session 0.18% lower at $11.00 and with a total volume of 967,690 shares traded. The Company’s shares have gained 4.76% on an YTD basis. The stock is trading below its 50-day moving average by 0.05%. Furthermore, shares of Pinnacle Entertainment have an RSI of 46.67. The complimentary notes on PNK can be downloaded in PDF format at:

http://www.activewallst.com/registration-3/?symbol=PNK

Penn National Gaming Inc. (NASDAQ: PENN)

At the closing bell on Tuesday, shares in Wyomissing, Pennsylvania-based Penn National Gaming Inc. saw a slight decline of 0.73%, ending the day at $13.59. The stock recorded a trading volume of 1.25 million shares, which was above its three months average volume of 963,440 shares. The Company’s shares are trading 12.28% below their 50-day moving average. Moreover, shares of Penn National Gaming, which owns and manages gaming and racing facilities, and operates video gaming terminals with a focus on slot machine entertainment, have an RSI of 29.78. On June 02nd, 2016, research firm Morgan Stanley upgraded the Company’s stock rating from ‘Underweight’ to ‘Equal-Weight’. Register for free and access the latest research on PENN at:

http://www.activewallst.com/registration-3/?symbol=PENN

Caesars Entertainment Corp. (NASDAQ: CZR)

Las Vegas, Nevada-based Caesars Entertainment Corp.’s stock ended the day 2.33% higher at $7.91 and with a total volume of 325,410 shares traded. The Company’s shares have gained 7.18% in the last month, 20.40% over the previous three months, and 0.25% on an YTD basis. The stock is trading 4.90% above its 50-day moving average and 5.46% above its 200-day moving average. Additionally, shares of Caesars Entertainment, which through its subsidiaries, provides casino-entertainment and hospitality services in the U.S. and globally, have an RSI of 49.43. Get free access to your research report on CZR at:

http://www.activewallst.com/registration-3/?symbol=CZR

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441785

LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Technology industry. Companies recently under review include Fitbit, CommScope, Sensata Technologies, and FLIR Systems. See our complete report on Fitbit at:

http://www.activewallst.com/registration-3/?symbol=FIT

Today, AWS is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/

The fast-evolving Technology sector is experiencing a slowdown this year, but the overall outlook for the space remains optimistic. Let us see how this is affecting some of the big names in the industry. Register with us now for your free membership and more research reports at:

http://www.activewallst.com/register/

Active Wall St takes a brief technical look at how each of the companies mentioned above have performed at the close of Tuesday’s session and over the last few trading sessions.

Fitbit Inc. (NYSE: FIT)

San Francisco, California headquartered Fitbit Inc.’s stock finished Tuesday’s session at $12.00, climbing 0.93%. A total volume of 10.14 million shares was traded, which was above their three months average volume of 9.11 million shares. The Company’s shares are trading below their 50-day moving average by 18.90%. Moreover, shares of Fitbit, which provides wearable health and fitness tracking devices, have a Relative Strength Index (RSI) of 31.65. On June 09th, 2016, research firm Wedbush initiated an ‘Outperform’ rating, issuing a target price of $18 on the Company’s stock.

CommScope Holding Co. Inc. (NASDAQ: COMM)

Shares in Hickory, North Carolina headquartered CommScope Holding Co. Inc. ended yesterday’s session 1.72% higher at $29.01 with a total volume of 1.34 million shares traded. The stock has gained 6.19% in the previous three months and 12.05% on an YTD basis. The Company’s shares are trading 4.25% above their 200-day moving average. Moreover, shares in CommScope Holding, which provides infrastructure solutions for communications networks globally, have an RSI of 32.53. On June 16th, 2016, research firm Credit Agricole initiated a ‘Buy’ rating, issuing a target price of $40 on the Company’s stock. Sign up for your research report on COMM at:

http://www.activewallst.com/registration-3/?symbol=COMM

Sensata Technologies Holding N.V. (NYSE: ST)

On Tuesday, Almelo, the Netherlands-based Sensata Technologies Holding N.V.’s stock rose 3.87% to close the day at $33.31. A total volume of 3.38 million shares was traded, which was above their three months average volume of 1.48 million shares. The Company’s shares are trading 8.36% below their 50-day moving average. Additionally, shares of Sensata Technologies Holding, which through its subsidiaries, develops, manufactures, and sells sensors and controls, have an RSI of 34.99. Register for free and download your research report on ST at:

http://www.activewallst.com/registration-3/?symbol=ST

FLIR Systems Inc. (NASDAQ: FLIR)

Shares in Wilsonville, Oregon headquartered FLIR Systems Inc. ended the day 2.10% higher at $29.69. A total volume of 959,410 shares was traded, which was above their three months average volume of 802,680 shares. The stock has gained 6.62% since the start of this year. The Company’s shares are trading below their 200-day moving average by 0.45%. Furthermore, shares of FLIR Systems, which designs, develops, manufactures, and markets thermal imaging, visible-light imaging systems, locater systems, measurement and diagnostic systems, and threat-detection solutions globally, have an RSI of 41.03. Research report on FLIR is available for free at:

http://www.activewallst.com/registration-3/?symbol=FLIR

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated directly or indirectly for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441782

NEW YORK, NY and PITTSBURGH, PA / ACCESSWIRE / June 29, 2016 / RenovaCare, Inc., (OTCQB: RCAR), a developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies*, released behind-the-scenes video footage of its medical device for spraying a patient’s own stem cells onto burns and wounds for rapid self-healing. The footage includes compelling first-hand testimony and before-and-after images of a State Trooper’s rapid, scar-free recovery from severe burns to over one-third of his body. Click here to watch the video.

This comes just weeks after the company successfully completed the engineering, studies, and associated efforts required for submission of foundational 510(k) filing the U.S. Food and Drug Administration (FDA) for spraying saline for wound irrigation. A successful 510(k) submission is an important benchmark in medical device development and will enable the marketing of the device, and helps meet the threshold for undertaking clinical research to support additional indications and uses of the device.

Prominently featured in the short presentation is RenovaCare, Inc. President and CEO, Thomas Bold, who explains the science behind the SkinGun™ and what the future holds for thousands of burn victims, wound and skin disease patients who would benefit from this type of medical treatment. The estimated addressable SkinGun™ market is $45 billion.

“Now that we’ve processed the necessary work for our 510(k) filing, we are excited to provide the public a sneak peek inside the world of RenovaCare, Inc. and share our stem cell therapy technology for the regeneration of the body’s largest organ, the skin,” said Bold.

*RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the company’s planned or filed submissions to the U.S. Food and Drug Administration, if any, will be accepted or cleared by the FDA.

About RenovaCare

RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs, and novel medical grade liquid sprayer devices.

In addition to its liquid spray devices for wound irrigation, the company’s pipeline products under development target the body’s largest organ, the skin. The RenovaCare CellMist™ System will use the patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the U.S. alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.

For additional information, please call Drew Danielson at: 888-398-0202 or visit: http://renovacareinc.com.

To receive future press releases via email, please visit: http://renovacareinc.com/investors/register/.

Follow us on Twitter https://twitter.com/Renovacare_inc or follow us on Facebook https://www.facebook.com/renovacarercar.

For answers to frequently asked questions, please visit our FAQ’s page: http://renovacareinc.com/investors/faqs/.

Media Contact:

TrendLogic
Dwain Schenck
800-992-6299
dwain@trendlogicpr.com

Social Media Disclaimer

Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:

• Facebook
• Twitter

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company’s technologies, technical problems with the Company’s research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: RenovaCare, Inc.

ReleaseID: 441741

LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Regional – Midwest Banks industry. Companies recently under review include KeyCorp., Huntington Bancshares, U.S. Bancorp, and Fifth Third Bancorp. See our complete report on KeyCorp. at:

http://www.activewallst.com/registration-3/?symbol=KEY

Today, AWS is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/

The Regional Midwest Banking industry includes all depository companies in the Midwest area of the United States. Performance of players in this space is dependent on economic activities within the region. Let us see what is affecting some of the big names in the industry. Register with us now for your free membership and more research reports at:

http://www.activewallst.com/register/

Active Wall St takes a brief technical look at how each of the aforementioned companies have performed over the last few trading sessions.

KeyCorp. (NYSE: KEY)

Cleveland, Ohio headquartered KeyCorp.’s stock finished Tuesday’s session 3.69% higher at $10.67. A total volume of 29.02 million shares was traded, which was above their three months average volume of 12.63 million shares. The Company’s shares are trading below their 200-day moving average by 11.37%. Furthermore, shares of KeyCorp., which operates as the bank holding Company for KeyBank National Association that provides various retail and commercial banking services to individual, corporate, and institutional clients in the U.S., have a Relative Strength Index (RSI) of 32.56.

Huntington Bancshares Inc. (NASDAQ: HBAN)

On Tuesday, shares in Columbus, Ohio headquartered Huntington Bancshares Inc. ended the session at $8.37, up 3.46%. The stock recorded a trading volume of 17.51 million shares, which was above its three months average volume of 11.11 million shares. The Company’s shares are trading 15.43% below their 50-day moving average. Moreover, shares of Huntington Bancshares, which operates as a holding Company for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services, have an RSI of 28.13. The complimentary research on HBAN can be downloaded at:

http://www.activewallst.com/registration-3/?symbol=HBAN

U.S. Bancorp (NYSE: USB)

Minneapolis, Minnesota headquartered financial services holding Company, U.S. Bancorp’s stock ended yesterday’s session 1.01% higher at $39.08. A total volume of 10.10 million shares was traded, which was higher than their three months average volume of 7.46 million shares. The Company’s shares are trading 5.09% below their 200-day moving average. Additionally, shares of U.S. Bancorp, which provides a range of financial services in the U.S., have an RSI of 31.67. Register for free and access the latest research report on USB at:

http://www.activewallst.com/registration-3/?symbol=USB

Fifth Third Bancorp (NASDAQ: FITB)

At the close on Tuesday, shares in Cincinnati, Ohio headquartered Fifth Third Bancorp recorded a trading volume of 12.73 million shares, which was above their three months average volume of 7.46 million shares. The stock finished 2.34% higher at $16.64. The Company’s shares are trading below their 200-day moving average by 7.74%. Furthermore, shares of Fifth Third Bancorp, which operates as a diversified financial services Company in the U.S., have an RSI of 35.75. On June 07th, 2016, research firm Susquehanna downgraded the Company’s stock rating from ‘Positive’ to ‘Neutral’. The complete research report on FITB is available for free at:

http://www.activewallst.com/registration-3/?symbol=FITB

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated directly or indirectly for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441781

LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall ST announces its post-earnings coverage on Carnival Corp. (NYSE: CCL). On Tuesday, June 28, 2016, the company announced its Q2 fiscal 2016 financial results. The cruise-ship company’s earnings beat market expectations as it nearly tripled on the back of lower fuel costs. Furthermore, the company announced a $1 billion share repurchase program. Register with us now for your free membership and see our complete earnings coverage on this equity at:

http://www.activewallst.com/register/

Today, AWS is promoting its earnings coverage on CCL. Get all of our free coverage by signing up to http://www.activewallst.com/registration-3/?symbol=CCL.

Earnings Reviewed

For the quarter ended on May 31, 2016, Carnival reported earnings of $605 million, or $0.80 per share, up from $222 million, or $0.29 per share, in the year ago period. Earnings, adjusted for non-recurring gains, rose to $0.49 in Q2 FY16 from $0.25 per share in Q2 FY15, surpassing analysts’ consensus estimate of $0.39 per share. Revenue for Q2 FY16 was $3.71 billion as compared to revenue of $3.59 billion in Q2 FY16, and came in above market estimates of $3.68 billion.

The company which operates around 100 ships around the globe has reaped the benefits from the collapse of fuel prices from above $100 per barrel to below $30 per barrel in the past two years. The company noted that changes in fuel prices and currency exchange rates contributed $0.04 per share to Q2 FY16 earnings. Excluding currency effects, net revenue yields (net revenue per available lower birth day) rose 3.6%, above the prior estimate for an increase of 1.5% to 2.5%. Excluding fuel expenses, net cruise costs declined 1.9% compared with forecast for an increase of between 0.5% and 1.5%.

Booking Advance but concerns from Brexit

Carnival said that advance reservations for the remainder of the calendar year 2016 were well ahead of the prior year at slightly higher prices, yet with lower volumes as there are fewer inventories available for sales as compared to last year. Advance customers booking should help to lower the impact of the current market volatility due to Britain’s decision to exit the European Union on June 24, 2016. The British pound, which represents 30% of Carnival’s currency exposure, reached a 31-year low after the referendum and can negatively impact earnings if it stays depressed.

Carnival eyes Chinese market

Carnival has also stated its desire to increase capacity in the lucrative Chinese market. The company plans to reduce European capacity by about 5% in favour of growing more in the burgeoning Chinese market. The leisure travel and cruise operator plans to increase capacity by more than 30% in 2017 compared to a 60% increase this year. China accounts for about 5% of the Carnival’s global capacity, and the company expects to increase this capacity to 6% by 2017.

Share Repurchase and Dividend

Carnival has authorized the buyback of $1 Billion worth of stock. Since October 2016, the company has already repurchased $1.9 Billion worth of shares, signalling their confidence moving forward.

The company also paid a quarterly dividend of $0.35 per share, which was paid on June 17, 2016 to shareholders of record on May 27, 2016. This represents a $1.40 annualized dividend and a yield of 3.21%. The quarterly dividend was higher than previous quarterly dividend of $0.30.

Guidance

For Q3 FY16, Carnival expects net revenue yields to be between 2% to 3%, and adjusted earnings to be in the range of $1.83 to $1.87, from the prior guidance of $1.83 to $1.87 per share. For the fiscal year ending in November, 2016, the company expects adjusted earnings to be in the range of $3.25 to $3.35 on a 3.5% increase in net revenue yields from the prior guidance of $3.20 to $3.40 per share.

Stock Performance

Carnival’s share gained 0.21% closing at $43.73. The stock hit an intraday high of $46.16, post its earnings release. Volume for the day was 14.38 million shares, which was higher than the stock’s 3-month average volume of 4.48 million. Shares of Carnival have declined 10.84% in the past one week, since the British referendum.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated directly or indirectly for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441784

LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers – Major industry. Companies recently under review include Pfizer, Merck, AbbVie, and Johnson & Johnson. See our complete report on Pfizer at:

http://www.activewallst.com/registration-3/?symbol=PFE

Today, AWS is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/

The Healthcare sector has been viewed by a number of investors as a safe haven during uncertain times. Let us see how this is affecting some of the big names in the industry. Register with us now for your free membership and more research reports at:

http://www.activewallst.com/register/

Active Wall St looks at the performance of each of the companies mentioned above following yesterday’s last close and over the last few trading sessions.

Pfizer Inc. (NYSE: PFE)

New York headquartered a biopharmaceutical Company, Pfizer Inc.’s stock finished Tuesday’s session 1.89% higher at $34.44 with a total volume of 23.74 million shares traded. The Company’s shares have advanced 15.56% in the previous three months and 8.73% since the start of this year. The stock is trading 1.81% above its 50-day moving average and 8.11% above its 200-day moving average. Additionally, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products globally, have a Relative Strength Index (RSI) of 52.39. On June 20th, 2016, research firm Jefferies reiterated its ‘Buy’ rating with a decrease of the target price to $40 a share from $42 a share for the Company’s stock.

Merck & Co. Inc. (NYSE: MRK)

On Tuesday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 12.74 million shares, which was above their three months average volume of 8.73 million shares. The stock ended the session 0.49% higher at $55.58. The Company’s shares have advanced 5.29% in the previous three months and 7.01% on an YTD basis. The stock is trading 0.18% above its 50-day moving average and 6.23% above its 200-day moving average. Moreover, shares of Merck & Co., which provides health care solutions globally, have an RSI of 47.20. Sign up for your research report on MRK at:

http://www.activewallst.com/registration-3/?symbol=MRK

AbbVie Inc. (NYSE: ABBV)

Shares in North Chicago, Illinois-based AbbVie Inc. closed the day 2.23% higher at $59.99. The stock recorded a trading volume of 9.89 million shares, which was higher than its three months average volume of 8.32 million shares. The Company’s shares have gained 6.26% over the previous three months and 3.31% on an YTD basis. The stock is trading 4.64% above its 200-day moving average. Additionally, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products globally, have an RSI of 46.12. On June 08th, 2016, research firm Morgan Stanley downgraded the Company’s stock rating from ‘Overweight’ to ‘Equal-Weight’. Register for free and download the research report on ABBV at:

http://www.activewallst.com/registration-3/?symbol=ABBV

Johnson & Johnson (NYSE: JNJ)

At the close, shares in New Brunswick, New Jersey-based Johnson & Johnson finished at $118.23, gaining 1.44%. The stock recorded a trading volume of 10.07 million shares, which was above its three months average volume of 7.04 million shares. The Company’s shares have advanced 4.57% in the last one month, 9.26% in the previous three months, and 16.76% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 3.87% and 14.08%, respectively. Furthermore, shares of Johnson & Johnson, which together with its subsidiaries, research and develop, manufacture, and sell various products in the health care field globally, have an RSI of 64.81. The research report on JNJ is available for free at:

http://www.activewallst.com/registration-3/?symbol=JNJ

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated directly or indirectly for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441780

LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces its coverage of market signals with highlight on these Top Gainers from Monday’s session: ReachLocal Inc. (NASDAQ: RLOC), Xencor Inc. (NASDAQ: XNCR), and Twilio Inc. (NYSE:TWLO). Register with us now for your free membership and get more on our signal alert and insight for ReachLocal at:

http://www.activewallst.com/registration-3/?symbol=RLOC

Stock Market Performance

On Tuesday, June 28, 2016, U.S. Stock indexes turned around showing first signs of recovery as the Dow shot up more than 200 points after the turmoil in the stock markets around the world, in the wake of the Britain’s referendum to exit the European Union. The Dow Jones industrial average gained 269.48 points, or 1.57%,

The S&P 500 index was up 1.78% and the Nasdaq composite gained 2.12%.

Today, AWS is promoting its market signals coverage with emphasis on RLOC, XNCR, and TWLO. Get all of our reports for free by signing up to http://www.activewallst.com/register/.

We take a look at some of the biggest gainers at the close of yesterday’s trading session:

Top Gainers – ReachLocal

On Tuesday, shares of ReachLocal Inc. skyrocketed 169.82% to close at $4.56, after Gannett Inc. (NYSE: GCI), the largest U.S. newspaper by total daily circulation, announced that it had reached a definitive agreement to acquire ReachLocal.

Gannet, the publisher of USA Today said it would pay $4.60 per share in cash for ReachLocal, which represents a premium of 188% to its closing price on Friday, June 24, 2016. At $4.60 per share, the total value of the deal comes to approximately $156 million. The deal is expected to be completed by the third quarter of 2016. The acquisition of ReachLocal, which has more than 16,000 customers, is expected to expand Gannett’s digital revenue by about 50%.

At the close on Tuesday, the stock recorded trading volume of 5.12 million shares, which was higher than its three months average volume of 98,828. Reachlocal’s shares have advanced 176.36% since the beginning of 2016.

Following yesterday’s session and news, Gannet’s shares declined 1.98% to close at $13.35.

Top Gainers – Xencor

Shares of biotech firm Xencor Inc. soared on Tuesday, June 28, 2016, by 32.06% to $16.56 after the company announced an agreement with Swiss drug giant Novartis. Under the deal, Novartis will pay Xencor $150 million, and potentially much more in the future, as the companies collaborate to develop and commercialize two experimental cancer drugs, one for acute myeloid leukemia and the other for B-cell malignancies.

Xencor will have commercialization rights in the U.S., while Novartis will have rights in the rest of the world. Xencor’s shares had closed at $12.56 in the previous trading session, and yesterday after opening higher at $15.10, the rally took the share price to an intraday high of $18.19 which also marked the stock’s highest level since it peak price on September 21, 2015 at $18.95. Since the beginning of 2016, the stock has advanced 13.27%.

Top Gainers – Twilio

Twilio Inc., the first venture-backed Bay Area tech company to go public in 2016, continued its run on Tuesday after a Brexit-induced drop last Friday and Monday, June 27, as the stock closed up by 9.80% at $29.92.

Twilio IPOed at $15 a share on Thursday, June 24, 2016, surging 91% to reach $28 in a single trading session. However, the company could not maintain the momentum as global stock markets went troubled waters following the Brexit’s shock.

Twilio runs a cloud-based API that allows software developers to programmatically make and receive phone calls, text messages and video chats. The company has big name clients using its services such as Facebook’s (NASDAQ: FB) Whatsapp, Nordstrom (NYSE: JWN), Coca Cola (NYSE: KO) among others.

Twilio boast of a strong financial record with a top line growing at a pace of 86% on Y-o-Y basis, while the company has also reported narrowing losses and improving adjusted EBITDA margin.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441786

BEDMINSTER, NJ / ACCESSWIRE / June 29, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has entered into a material transfer agreement with Luna Innovations Inc. (NASDAQ: LUNA), a company with broad expertise in materials technology and applied R&D in the health sciences, to test the feasibility of incorporating taurolidine into electrospun nanofibers. Luna will leverage its existing government-funded research and biomaterials expertise to create nanofibers loaded with CRMD-006, CorMedix’s proprietary formulation of taurolidine, to create unique scaffolds with anti-microbial and anti-inflammatory properties that can be used primarily for wound closure and burn care. Under the agreement, Luna and CorMedix will also explore opportunities to commercialize any product, invention, or derivative developed under the collaboration.

Chronic non-healing wounds and burns expose patients to risk of infections that can complicate healing and have the potential to progress into life-threatening conditions. Electrospun fiber meshes use synthetic and natural polymers to improve patient outcomes relative to conventional dressings. Unfortunately, few dressings have been developed that allow delivery of analgesics or therapeutics while effectively preventing infections. By combining CRMD-006 with Luna’s electrospinning technology, if feasible, the companies may advance a novel anti-microbial medical device for use wound care that can simultaneously provide wound management, pain relief, and anti-microbial activity.

Randy Milby, chief executive officer of CorMedix, stated, “As we’ve discussed, identifying partnership opportunities and expanding the potential of our taurolidine platform is a key component of our growth strategy. This agreement with Luna marks our first such collaboration in the medical device space and we are optimistic about the possibility of creating nanofiber meshes with taurolidine’s proven anti-microbial and anti-inflammatory properties.”

My E. Chung, president and chief executive officer of Luna Innovations, added, “We are excited to have this opportunity to leverage our expertise and be a part of this significant development. Partnering with CorMedix to explore this challenge is yet another example of the unique capabilities of our Technology Development Division.”

About Luna

Luna Innovations Incorporated (www.lunainc.com) is organized into two business segments, which work closely together to turn ideas into products: a Technology Development segment and a Products and Licensing segment. Luna’s business model is designed to accelerate the process of bringing new and innovative technologies to market. Luna’s Technology Development segment provides research and development in the areas of advanced materials, sensing and instrumentation, and health sciences. Luna’s Product segments develop high speed optics and high performance fiber optic test products that provide unique capabilities for the aerospace, automotive, energy, defense, and telecommunications industries. Luna develops, manufactures and markets high definition fiber optic sensing products and fiber optic test and measurement instrumentation, and packages optoelectronic semiconductors into high-speed optical receivers (HSOR products), custom optoelectronic subsystems (Optoelectronics products) and Terahertz (THz) instrumentation.

About CorMedix Inc.

CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase 3 clinical study of a novel anti-infective solution Neutrolin in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix’s first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also has designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information visit: www.cormedix.com.

For Investors & Media:

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: CorMedix’s ability to enter into, execute upon and maintain collaborations with third parties for its development and marketing programs, including the collaboration with Luna Innovations Inc.; the results of studies regarding Neutrolin® conducted by us and others; the cost, timing and results of the planned Phase 3 trials for Neutrolin® in the U.S.; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix’s product candidates, including marketing of Neutrolin in countries other than Europe; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; the risks associated with the launch of Neutrolin in new markets; CorMedix’s ability to maintain its listing on the NYSE MKT; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources; the outcome of clinical trials of CorMedix’s product candidates and whether they demonstrate these candidates’ safety and effectiveness; CorMedix’s ability to identify and enter into strategic transactions; CorMedix’s dependence on its collaborations and its license relationships; achieving milestones under CorMedix’s collaborations; CorMedix’s dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers, sales and marketing organizations, and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

SOURCE: CorMedix Inc.

ReleaseID: 441788

MONTREAL, QC / ACCESSWIRE / June 29, 2016 / Peak Positioning Technologies Inc. (CSE: PKK) (OTC Pink: PKKFF) (“Peak” or the “Company”) today announced that its Chinese subsidiary, Asia Synergy Technologies Ltd. (“AST”), has been registered as an operating entity legally authorized to conduct business in China. AST was registered in Shanghai and has established its head office in the City of Wuxi in the province of Jiangsu.

The announcement marks a major milestone for the Company and clears the path to allow AST to begin to take over some of the plastic raw materials distribution activities of the Zhonghai Wanyue Group’s (“ZHWY Group”) subsidiaries as per the strategic partnership agreement between Peak and ZHWY Group Chairman, Mr. Jiang Wang.

Although the vast majority of AST’s operations are expected to be facilitated by the Gold River Fintech web-based platform, the company is also expected to engage in some offline transactions while Gold River hits its stride. “We started discussions with a handful of clients and suppliers while the company registration process was running its course,” commented AST CEO, Mr. Liang Qiu. “Until we get them using the online platform, we’ll start with some offline transactions, very similar to the transactions they are currently doing with ZHWY Group subsidiaries, so nothing will change for them in the short run.”

“We’ll eventually have the transactions go through Gold River, but for now, starting with offline transactions will ensure a smooth transition to Gold River and allow AST to generate revenues more quickly,” Mr. Qiu went on to say.

More Exercise of Warrants and Conversion of Debentures

Peak also announced that the Company issued 12,000 common shares at a price of $0.05 per share and 7,500,000 common shares at a price of $0.025 as a result of the exercise of common share purchase warrants. The Company also issued 536,220 additional common shares at a price of $0.05 per share as a result of the exercise of the conversion feature of secured convertible debentures.

The announced transactions combine to add $188,100 to the Company’s cash flow and remove $26,811’s worth of short-term debt from its books.

About Peak Positioning Technologies Inc.:

Peak Positioning Technologies Inc. is an IT portfolio management company whose mission is to assemble, finance and manage a portfolio of high-growth-potential companies and assets in some of the fastest growing tech sectors in China, including Fintech, e-commerce and cloud-computing. Peak provides its shareholders with exceptional growth potential by giving them access to the fastest growing sectors of the world’s fastest growing economy. For more information: http://www.peakpositioning.com

Contact information:

Cathy Hume
CEO
CHF Investor Relations
Phone: 416-868-1079 ext.: 231
Email: cathy@chfir.com

Or

Carl Desjardins
Managing Partner
Paradox Public Relations Inc.
Phone: 514-341-0408  
Email: carldesjardins@paradox-pr.ca

Or

Johnson Joseph
President and CEO
Peak Positioning Technologies Inc.
Phone: 514-340-7775 ext.: 501
Email: investors@peakpositioning.com

SOURCE: Peak Positioning Technologies Inc. 

ReleaseID: 441791